Biotechnology company, SCYNEXIS, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oral ibrexafungerp for the treatment of vulvovaginal...

SCYNEXIS, Inc. announced this week positive top-line results for its Phase 3 VANISH-306 study investigating the safety and efficacy of oral ibrexafungerp, a novel broad-spectrum antifungal, as a treatment...

A commonly used medication, fluconazole, used to treat vaginal yeast infections, is linked to higher rates of miscarriage if used during pregnancy, found new research published in CMAJ (Canadian Medical...